Checkpoint Therapeutics Inc (CKPT)

NASDAQ
1.300
+0.040(+3.17%)
After Hours
1.280
-0.020(-1.531%)
- Real-time Data
  • Volume:
    292,247
  • Day's Range:
    1.230 - 1.310
  • 52 wk Range:
    0.960 - 4.640

CKPT Overview

Prev. Close
1.26
Day's Range
1.23-1.31
Revenue
118K
Open
1.25
52 wk Range
0.96-4.64
EPS
-0.841
Volume
292,247
Market Cap
127.26M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
453,781
P/E Ratio
-1.28
Beta
1.77
1-Year Change
-53.74%
Shares Outstanding
97,891,442
Next Earnings Date
Nov 04, 2022
What is your sentiment on Checkpoint Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Checkpoint Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Checkpoint Therapeutics Inc Company Profile

Checkpoint Therapeutics Inc Company Profile

Employees
14

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company’s lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
  • Target price raised to $ 23, prepare for a stratospheric rise at any moment
    0
    • When?
      0
  • Target price $ 22,50
    0
    • Long at 2.40s for possible squeeze later. 🚀🚀👍👍
      0
      • No call options for this stock?
        1
        • I will go up. I have heavy position. 10 shares
          1
          • It
            1
          • What?
            0
        • CKPT $4.16 +12.13% @ Close!
          0
          • CKPT $3.99 @ 01:14 PM ET .... selling longs from $2.77 then $2.88.
            0
            • CKPT $3.18 +17.34% @ Close! Bringing stop up to b/e at $2.77
              0
              • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
                1
                • CKPT $2.78 +10.32% @ close!
                  0
                  • First daily interval close above 70-day simple moving average since falling below on 10/19//20.  RSI bullish at 61.776 and MACD now just above 0.00.  Technicals bullish
                    0